STOCKHOLM, Feb. 21, 2022 /PRNewswire/ — Implantica AG (publ), an emerging and speedy increasing med-tech enterprise that is groundbreaking innovative options to handle chronic wellness ailments with good implants, these days announces that it has concluded an intensive eHealth patent filing that exceeded 25,000 web pages, the fruits of a full year’s do the job of Implantica’s workforce and patent attorneys. The filing encompasses 59 new patent apps targeted on Implantica’s eHealth system and a broad selection of purposes.
This detailed filing signifies a substantial strengthening and term-extension of Implantica’s patent security. The patent programs will give basic protection for the eHealth platform in general and prolong the scope and term of the patent defense for the pipeline solutions. This landmark submitting will – in the years to come – be divided into numerous hundred particular person patent purposes, making patent security for the platform and the pipeline products as the growth progresses. The most significant eHealth application comprised 1,950 webpages and consisted of 596 webpages of drawings, which is about 100-fold the measurement of a regular patent. For the duration of 2021, Implantica validated 824 issued patents in full in numerous countries.
“Implantica has intended its eHealth system to be in the forefront of the eHealth revolution with the chance to transform treatment on length thus preserving costs for society. With this spectacular 1-yr patent perform, we will have the chance to maintain that eHealth edge in the marketplace or license engineering to other organizations. These types of systematic and superior patent operate builds the foundation of a successful extensive-time period business enterprise. We are building the platform for an remarkable small business likely going forward and transforming the cure landscape for patients,” explained Peter Forsell, CEO of Implantica.
For even more facts, you should get hold of:
Nicole Pehrsson, Trader Relations
Phone (CH): +41 ()79 335 09 49
Implantica is shown on Nasdaq Initially North Leading Development Current market in Stockholm.
The company’s Certified Adviser is FNCA Sweden AB, +46 ()8 528 00 399, [email protected]
The information was sent for publication, by means of the agency of the get hold of particular person established out earlier mentioned, on February 21, 2022 at 08:00 a.m. CET.
Implantica is a medtech business committed to bringing highly developed technological innovation into the human body. Implantica’s guide solution, RefluxStop™, is a CE-marked implant for the avoidance of gastroesophageal reflux that will possibly produce a paradigm shift in anti-reflux treatment method as supported by productive medical demo effects. Implantica also focuses on eHealth inside the entire body and has developed a wide, patent guarded, product pipeline primarily based partly on two system systems: an eHealth platform made to keep track of a broad range of health parameters, handle therapy from inside the body and connect to the caregiver on distance and a wireless energising platform developed to electric power remote controlled implants wirelessly by means of intact skin. Implantica is listed on Nasdaq Very first North Leading Development Industry (ticker: IMP A SDB).
Pay a visit to www.implantica.com for even more data.
This facts was introduced to you by Cision http://information.cision.com
The following files are available for obtain: